In three out of five of these cases, the reasons for non-adherence to MTB recommendations were unknown, in the cases of a NSCLC with NTRK fusion or with BRAF p.Val600Glu mutation; however, stable disease under non-matched therapy precluded MTB recommendation implementation. The gene discussed is BRAF; the disease is non-small cell lung carcinoma.